+ T cell responses to lymphocytic choriomeningitis virus infection and worsened experimental autoimmune encephalomyelitis (EAE). These functions of NLRC3 were executed in a T-cell-intrinsic fashion: NLRC3 reduced K63-linked ubiquitination of TNF-receptor-associated factor 6 (TRAF6) to limit NF-kB activation, lowered phosphorylation of eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and diminished glycolysis and oxidative phosphorylation. This study reveals an unappreciated role for NLRC3 in attenuating CD4 + T cell signaling and metabolism.
In Brief NLRC3 limits inflammatory signaling in myeloid cells, but its role in T cells has been unclear. Uchimura et al. reveal that T cell expression of Nlrc3 restricts autoimmune and virus-specific CD4 + T cell responses by attenuating T cell signaling and metabolic pathways in CD4 + T cells.
SUMMARY
Appropriate immune responses require a fine balance between immune activation and attenuation. NLRC3, a non-inflammasome-forming member of the NLR innate immune receptor family, attenuates inflammation in myeloid cells and proliferation in epithelial cells. T lymphocytes express the highest amounts of Nlrc3 transcript where its physiologic relevance is unknown. We show that NLRC3 attenuated interferon-g and TNF expression by CD4 + T cells and reduced T helper 1 (Th1) and Th17 cell proliferation. Nlrc3 À/À mice exhibited increased and prolonged CD4 + T cell responses to lymphocytic choriomeningitis virus infection and worsened experimental autoimmune encephalomyelitis (EAE). These functions of NLRC3 were executed in a T-cell-intrinsic fashion: NLRC3 reduced K63-linked ubiquitination of TNF-receptor-associated factor 6 (TRAF6) to limit NF-kB activation, lowered phosphorylation of eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and diminished glycolysis and oxidative phosphorylation. This study reveals an unappreciated role for NLRC3 in attenuating CD4 +
INTRODUCTION
Pattern-recognition receptors (PRRs) are indispensable for innate immune responses. PRRs are receptors or sensors that detect pathogen-associated molecular patterns (PAMPs) from microbes and damage-associated molecular patterns (DAMPs) from cellular sources either directly or indirectly. In most cases, these molecules function to initiate innate immune and inflammatory signaling cascades (Brubaker et al., 2015) . The nucleotide-binding domain and leucine-rich-repeat-containing (NLR) proteins are cytosolic PRRs and are known to sense or bind intracellular PAMPs and DAMPs. There are two groups of NLRs based on their functions: inflammasome-forming NLRs and non-inflammasomeforming NLRs (Allen, 2014; Guo et al., 2015) . Some of the beststudied inflammasome-forming NLRs, including NLRP1, NLRP3, and NLRC4, regulate the activation of caspase-1, which is necessary for the processing of key pro-inflammatory cytokines that drive innate immune responses to PAMPs and DAMPs. Upon activation by PAMPs or cellular disturbances, inflammasome NLRs undergo a conformational change that allows the recruitment and binding of the ASC (apoptotic-speck-containing protein with a CARD) adaptor and procaspase-1 to form a fibril-like macromolecular structure (Lechtenberg et al., 2014; Lu et al., 2014) . This leads to the catalytic cleavage and activation of caspase-1, which drives the subsequent catalytic cleavage and activation of IL-1 and IL-18. Non-inflammasome-forming NLRs-for example, CIITA, NLRC5, NOD1, and NOD2-demonstrate enhanced major histocompatibility gene expression and immune signaling. By contrast, an increasingly large group of NLRs negatively regulate innate immunity and inflammatory responses in the myeloid lineage. These include NLRP2 (Bruey et al., 2004) , NLRP4 (Lin et al., 2016; Cui et al., 2012) , NLRP6 (Anand et al., 2012) , NLRP12 Zaki et al., 2011) , NLRX1 (Allen et al., 2011; Xia et al., 2011) , NLRC5 (Cui et al., 2010) , and NLRC3 Zhang et al., 2014; Karki et al., 2016) , although some of these proteins have pleiotropic functions.
Murine NLRC3 reduces toll-like-receptor (TLR)-induced nuclear factor kappa B (NF-kB) activation through inhibition of the adaptor protein TNF-receptor-associated factor 6 (TRAF6) in peritoneal macrophages . NLRC3 also reduces stimulator of interferon genes (STING)-dependent innate immune activation in response to cytosolic DNA and cyclic di-GMP by blocking STING and TANK-binding kinase 1 (TBK1) interaction required for type 1 interferon (IFN) production (Zhang et al., 2014) . NLRC3 additionally plays a role in non-immune cells, where its association with PI3K blocks activation of the PI3K-dependent Akt kinase and inhibits mTOR pathways in colon epithelial cells (Karki et al., 2016) . Although its function has been studied in myeloid and epithelial cells, Nlrc3 expression in these cells is extremely low. Paradoxically, both mouse Nlrc3 and human NLRC3 show the highest expression in T cells and secondary lymphoid organs (Conti et al., 2005) ; however, the biologic role of NLRC3 in primary T cells remains to be elucidated. Although PRRs in general have been extensively analyzed in the innate immune system, there are few reports addressing their roles in adaptive immune cells. Nlrc3 is unique among NLRs because of its high expression in lymphocytes.
Herein, we used Nlrc3 À/À cells or mice to investigate the physiologic role of NLRC3 in T cell responses. We found that NLRC3 had a T-cell-intrinsic role in attenuating T cell proliferation and cytokine production upon T cell receptor (TCR) stimulation in part by reducing the immune signaling mediated by NF-kB, TRAF6, and 4E-BP1. Additionally, NLRC3 regulated cellular metabolism in a NF-kB-dependent fashion, marked by an attenuation of glycolysis, which is known to control both IFN-g secretion and cellular proliferation (Peng et al., 2016) . Nlrc3 À/À mice displayed increased CD4 + T cell responses to lymphocytic choriomeningitis virus (LCMV) infection and enhanced CD4 + T cell autoreactivity against self-antigens. Cumulatively, we reveal an unappreciated role for NLRC3 in directly regulating adaptive immunity through T-cell-intrinsic mechanisms.
RESULTS

Nlrc3
Is Down-regulated Upon T Cell Activation and Suppresses CD4 + T Cell Activation Figure 1A ). CD4 + T cells differentiated under Th0, Th1 (IL-12), and Th17 (IL-6 and TGF-b) cell conditions also showed decreased Nlrc3 expression 24 and 48 hr after anti-CD3 and anti-CD28 stimulation ( Figure 1B) , suggesting that T cell activation reduces Nlrc3 expression in Th0, Th1, and Th17 CD4 + T cells. To define the functional role of NLRC3 in T cells, we evaluated its role during T cell development in the thymus and spleen under homeostatic conditions. Eight-week-old Nlrc3 À/À mice had normal proportions of splenic and thymic T cell subsets, and cell numbers were similar to those in WT mice (Figures S1A-S1F). CD4 + or CD8 + T cells from WT and Nlrc3 À/À mice were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin or with anti-CD3 and anti-CD28 antibodies and analyzed for surface expression of CD25 (IL-2 receptor) and CD69, which are upregulated early after T cell activation. Compared with WT CD4 + T cells,
À/À CD4 + T cells expressed significantly greater percentages of CD25 ( Figure 1C , top panels) and CD69 ( Figure 1C , lower panels) 2-4 hr after PMA and ionomycin treatment, and the mean fluorescence intensity (MFI) for CD25 and CD69 was also increased for Nlrc3 À/À CD4 + T cells ( Figure 1C , right). Similar expression patterns were seen when T cells were stimulated with anti-CD3 and anti-CD28 antibodies ( Figure 1D ). In contrast to CD4 + T cells, Nlrc3 À/À CD8 + T cells expressed similar or slightly reduced amounts of those markers in comparison with WT CD8 + T cells under the same stimulatory conditions ( Figure S2 ). These findings suggest that NLRC3 suppresses the activation of CD4 + T cells.
NLRC3 Negatively Regulates Cytokine Expression by Activated CD4 + T Cells
The expression data above suggest that NLRC3 might affect T cell activity. Significantly greater percentages of Nlrc3 À/À CD4 + T cells than of WT cells were able to make IFN-g or TNF 24 hr after anti-CD3 and anti-CD28 stimulation, and the amount of cytokine expressed per cell was also increased for Nlrc3 (Figures 2A and 2B ), though the effect of Nlrc3 deletion on IL-2 expression was modest. In addition, the frequency of Nlrc3 À/À cells co-expressing IFN-g and TNF was nearly 4-fold higher than in WT T cells ( Figure 2C ). Nlrc3 À/À CD4 + T cells could produce more IFN-g, TNF, and IL-2 than WT cells, as shown by ELISA ( Figure 2D ). By contrast, CD8 + T cells purified from
Nlrc3
À/À mice showed no change or even slightly less expression of these cytokines than did WT CD8 + T cells. ( Figures   S3A-S3C ). In contrast to TCR-induced signals, NLRC3 did not affect inflammatory cytokine production by T cells after stimulation with a TLR agonist or IL-1b ( Figure S3D ). Collectively, these results suggest that NLRC3 limits cytokine production by CD4 + T cells. Figure S3 .
NLRC3
concentrations of anti-CD3 and anti-CD28 antibodies to induce proliferation across 3-5 days. At lower concentrations of anti-CD3 (1 or 2.5 mg/mL), there were approximately twice as many proliferating Nlrc3 À/À CD4 + T cells as WT cells (Figures 3A and 3B) . At the highest concentration of anti-CD3 (5 mg/mL), Nlrc3 À/À CD4 + T cells proliferated more than WT T cells early on, but this difference diminished by day 5 when >90% of the cells had proliferated in both groups ( Figure 3C ). More Nlrc3 À/À CD4 + T cells than WT T cells accumulated in these cultures, consistent with their increased proliferation and survival ( Figure 3D ). A similar analysis was performed for CD4 + T cells under Th1-and Th17-cell-polarizing conditions. There were approximately 2-to 3-fold more proliferating Nlrc3 À/À CD4 + T cells than WT cells at low and medium concentrations of anti-CD3 under Th1 (IL-12)-and Th17 (IL-6 and TGF-b)-cell-polarizing conditions ( Figure 3E ), though these differences diminished with the highest anti-CD3 concentration. These findings suggest that NLRC3 negatively regulates Th1 and Th17 cell proliferation when TCR stimulation is limited ( Figure 3E ). We found little impact of NLRC3 deficiency on naive CD25 lo CD44 lo CD4 + T cell proliferation after anti-CD3
and anti-CD28 stimulation ( Figure S4A ), and Nlrc3 deficiency had no apparent effect on CD8 + T cell proliferation ( Figures  S4B and S4C) . Also, there were minimal changes in the percentage of dead T cells in CD4 + and CD8 + T cell cultures ( Figure S4D ). mice than in WT mice at day 8, and there was a modest but sig- nificant increase in the total number of cytokine-producing CD4
+ T cells in Nlrc3
À/À mice ( Figure 4C ). These data indicate that NLRC3 is dispensable for resolving an acute infection but limits peak CD4 + T cell responses.
In contrast to LCMV-Armstrong, LCMVClone 13 replicates to a high titer and widely disseminates in WT mice and establishes a chronic infection. Immune control of LCMV-Clone 13 requires CD8 + T cells that are heavily dependent on the activity of CD4 + T cells and B cells. Nlrc3 À/À mice had significantly lower amounts of virus in serum than did WT mice at day 8 ( Figure 4D ). There were significantly more virus-specific tetramer-positive CD8 
NLRC3 Functions within CD4 + T Cells to Inhibit T Cell Accumulation and Expression of Pro-inflammatory Cytokines
The data above suggest that NLRC3 negatively regulated the CD4 + T cell response to LCMV, but the effect was modest, and a concern is that NLRC3 has known roles in other cell types, thus masking its function in T cells. Figure 5B ). Similarly, splenic Nlrc3 À/À SMARTA T cells were more frequent and numerous than WT SMARTA T cells in the same mice at day 8 ( Figure 5C , left two panels). The Nlrc3 À/À splenic T cells continued to be more abundant at day 42 ( Figure 5D , left two panels), whereas WT SMARTA T cell responses subsided in the same hosts. In addition to increased expansion, there were more Nlrc3 À/À SMARTA T cells that could make cytokine at early and late time points ( Figures 5C and 5D , right two panels). These findings suggest that CD4 + T cell expression of Nlrc3 limits cell expansion and maintenance over time during LCMV infection.
NLRC3 Reduces IFN-g Production in Autoreactive CD4
+ T Cells In Vitro
The above results indicate that NLRC3 attenuates prolonged T cell activation during a viral infection. We considered that NLRC3 might reduce T cell auto-reactivity in models of autoimmunity. To explore this issue, we bred Nlrc3 À/À mice with the 2D2 transgenic strain, which expresses a TCR specific to the myelin antigen, MOG . These data are consistent with the fact that NLRC3 acts within T cells to suppress IFN-g expression.
Nlrc3
-/-Mice Are More Susceptible to EAE Next, we examined the in vivo role of NLRC3 in the EAE model to determine whether it plays a role in a CD4
+ T-cell-driven disease model. Nlrc3 À/À mice were more susceptible to EAE than WT mice and had significantly higher clinical scores in the effector phase ( Figure 6C Figure 6F ). Collectively, these findings indicate that NLRC3 acts in a cell-intrinsic fashion to suppress CD4 + T cells in the EAE model.
To more broadly identify the genes that might be altered by NLRC3, we analyzed a public database of MS patients (Figure 6G) . We examined RNA sequencing (RNA-seq) data from the NCBI Gene Expression Omnibus (GEO) (Cao et al., 2015) to identify gene expression patterns relevant to human NLRC3 expression. Gene expression was compared in MOG-non- Figure 6H ). The heatmap showed that Nlrc3 À/À resulted in the elevation of a number of genes associated with Th1, Th17, and T cell activation, including Tnf, Ifng, Tbx21, Il17a, Il17f, and Nfatc1. This is consistent with the human data. Nlrc3 À/À T cells also showed elevated Foxp3 and Il4. It will be of interest in the future to perform similar analyses under Treg-or Th2-cell-inducing conditions.
NLRC3 Suppresses Immune Signaling in CD4 + T Cells
We next explored the signaling pathway(s) that NLRC3 uses to limit CD4 + T cell activation and proliferation. Purified Nlrc3 À/À CD4 + but not CD8 + T cells stimulated with anti-CD3 and anti-CD28 showed enhanced phosphorylation of p65 and STAT1, a marker for IFN-g signaling ( Figure 7A ). However, phosphorylation of ZAP70, a tyrosine kinase adaptor that lies downstream of CD3-zeta and is important for proximal TCR signaling, was not altered by NLRC3 (Figures 7B and S6A) . Additionally, NLRC3 did not affect the phosphorylation of PLC-g1, another molecule that is recruited to the TCR signaling complex (Figure S6B) . WT DCs induced the nuclear translocation of NFAT-1 from the cytoplasm of WT CD4 + T cells, and Nlrc3 (B) Percentage of SMARTA cells in peripheral blood at days 8, 22, and 42 after LCMV-Clone 13 infection (day 8: n = 3 recipients for WT uninfected, n = 3 recipients for Nlrc3
À/À , n = 10 recipients for WT with Clone 13 infection, n = 10 recipients for Nlrc3 À/À with Clone 13 infection; days 22 and 42: n = 3 recipients for WT uninfected, n = 3 recipients for Nlrc3 À/À uninfected, n = 8 recipients for WT with Clone 13 infection, n = 8 recipients for Nlrc3 À/À with Clone 13 infection).
(C) Percentage and total number of splenic SMARTA cells and intracellular cytokine staining for IFN-g, TNF, and IL-2 8 days after Clone 13 infection (n = 3 recipients for WT uninfected, n = 3 recipients for Nlrc3 À/À uninfected, n = 5 recipients for WT with Clone 13 infection, n = 5 recipients for Nlrc3 À/À with Clone 13 infection).
(D) Percentage and total number of splenic SMARTA cells and intracellular cytokine staining for IFN-g, TNF, and IL-2 at 42 days of Clone 13 infection (n = 3 recipients for WT uninfected, n = 3 recipients for Nlrc3 À/À uninfected, n = 8 recipients for WT with Clone 13 infection, n = 8 recipients for Nlrc3 À/À with Clone 13 infection). Each symbol represents one mouse. Data are from one experiment representative of two independent experiments and are shown as mean ± SEM. Statistical significance was determined by unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5 . CD4 + T cells showed a similar degree of NFAT-1 translocation ( Figure S6C ). T-bet and Eomes transcription factors (Szabo et al., 2002) are important for IFN-g transcription in T cells; however, T-bet and Eomes were similarly phosphorylated in Nlrc3 À/À and WT CD4 + T cells after DC-induced stimulation ( Figure S6D ). However, Nlrc3 À/À T cells showed more phosphorylated STAT1 than WT CD4 + T cells ( Figure S6D ). The inability to detect these differences by western blot, in contrast to RNA-seq, is most likely due to the sensitivity limit of western blots. Because NLRC3 inhibits mTOR pathways in colon epithelial cells (Karki et al., 2016) (legend continued on next page) detection for these in vivo samples (data not shown). These findings suggest that NLRC3 regulates canonical NF-kB signaling in CD4 + T cells.
NLRC3 interacts with TRAF6 in peritoneal macrophages to attenuate K63-linked ubiquitination of TRAF6, a posttranslational modification that activates TRAF6 in innate cells . To determine whether NLRC3 regulates this step to control NF-kB signaling in T cells, we performed a co-immunoprecipitation assay to evaluate K63-linked ubiquitination of TRAF6 in CD4 + T cells isolated from WT and Nlrc3 À/À mice. We detected faster K63-linked ubiquitination of TRAF6 in Nlrc3 À/À CD4 + T cells than in WT CD4 + T cells at the 5 min time point ( Figure 7F ). In addition, TRAF6 and p-p65 were more abundant in Nlrc3 À/À CD4 + T cells than in WT CD4 + T cells ( Figure 7F ). These findings suggest that NLRC3 negatively regulates K63-linked ubiquitination of TRAF6 and reduces downstream NF-kB signaling.
NLRC3 Diminishes Metabolic Pathways to Attenuate T Cell Activation in a NF-kB-Dependent Manner
T cell activation and differentiation are associated with metabolic rewiring (Pearce et al., 2013) , such that aerobic glycolysis is a metabolic hallmark of activated T cells and Th1 cell differentiation (Peng et al., 2016 Figure 7G ). Although the glycolytic responses were comparable between WT and Nlrc3 À/À CD4 + cells when exposed to glucose, Nlrc3
T cells reached a significantly higher maximum ECAR (glycolytic capacity) after the addition of the ATP synthase inhibitor oligomycin, which shuts down OXPHOS to force cells to use glycolysis as the main energy source ( Figure 7G ). Untreated WT or Nlrc3 À/À CD4 + T cells exhibited lower mitochondrial metabolic profiles than their activated counterparts. T cell activation increased the mitochondria respiration rate in both genotypes, but the increase in Nlrc3 À/À CD4 + T cells was significantly higher than that observed in WT CD4 + T cells. The absence of Nlrc3 in activated CD4 + T cells also resulted in higher usage of OXPHOS for driving ATP production (ATP-linked respiration) and maximized OXPHOS activity after cell exposure to FCCP (carbonylcyanide-4-trifluoromethoxyphenylhydrazone), which uncouples oxygen consumption from ATP production and raises OCR to a maximal value, as seen for the maximum ECAR measurement ( Figure 7H ). The higher glycolytic capacity, glycolytic reserve, and maximal mitochondrial respiration in active Nlrc3 À/À CD4 + T cells indicate a greater ability to operate at maximal metabolic capacity and cope with sudden ''high energy demand.'' This capability most likely fuels the energy necessary for the enhanced proliferation and cytokine production in Nlrc3 À/À CD4 + T cells.
We next assessed whether the higher glycolytic response in Figures 7I and S7A ). To exclude offtarget and toxic effects of BAY11-7082, we evaluated a different NF-kB inhibitor, QNZ, which is a quinazoline derivative (Tobe et al., 2003) . QNZ also eliminated the difference between WT and Nlrc3 À/À CD4 + T cells ( Figures 7J and S7B) . Treatment of unstimulated or anti-CD3-and anti-CD28-stimulated T cells with BAY11-7082 did not result in changes in cell death ( Figure S7C ) but did result in reduced NF-kB activation ( Figure S7D ). These results suggest that NLRC3 controls CD4 + T cell metabolism by limiting maximal glycolytic and mitochondrial metabolism and by attenuating TCR-induced glycolytic flux in an NF-kBdependent manner. In total, our findings indicate that NLRC3 attenuates CD4 + T cell responses by targeting pathways downstream of TCR signaling (TRAF6 ubiquitination and NF-kB activation) and by interfering with T cell metabolism. Thus, NLRC3 is an innate immune receptor that guards against excessive (F) WT and Nlrc3 À/À CD4 + T cells stimulated with anti-CD3 (5 mg/mL) and anti-CD28 (2 mg/mL) antibodies, and then endogenous TRAF6 immune-precipitation was performed. The western blot shows K63-linked ubiquitination (K63-Ub) of TRAF6.
(G) CD4 + T cells from spleens of WT or Nlrc3 À/À mice were stimulated or not with anti-CD3 and anti-CD28 antibodies for 24 hr and then assayed for ECA) or OCR.
Cells were measured over time and exposed (at the indicated time points) to glucose, oligomycin, and 2-DG for ECAR measurement or to oligomycin, FCCP, and rotenone for OCR assessment. ECARs and OCRs were recorded three times per condition. The basal ECAR, glycolysis (ECAR after glucose addition), glycolytic capacity (maximal ECAR after subtracting the ECAR following 2-DG exposure), and glycolytic reserve (difference between oligomycin-induced maximal ECAR and glucose-induced glycolytic flux) were calculated. (H) Cells were cultured as in (G) except that basal OCR, ATP-linked mitochondrial respiration (difference between basal respiration and OCR after the addition of oligomycin), maximal respiration (FCCP-induced maximal OCR minus the portion of nonmitochondrial OCR due to rotenone treatment), and spare respiratory capacity (difference between maximal OCR and basal respiration) were measured. T cell proliferation and cytokine expression and demonstrates crossover regulatory functions in adaptive immunity.
DISCUSSION
Immune regulatory pathways are critical for preventing overzealous and detrimental inflammation and autoimmunity. A prominent example is the adverse reaction associated with the use of immune checkpoint inhibitors in cancer treatment (Friedman et al., 2016) , which can result in severe autoimmunity. Although most studies of T cell checkpoint proteins have focused on molecules long known to be prominent in T cells (Sharpe and Pauken, 2018) , the discovery of alternative immune checkpoints is an area of active pursuit because of their relevance to cancer immunotherapy, sepsis control, and auto-immunity. In this study, we have described an unappreciated role for an innate immune receptor member during T cell responses to infection and T-cell-mediated diseases. NLRC3 exhibited an intrinsic role in T cells, and its deficiency in CD4 + T cells resulted in greater activation, proliferation, and inflammatory cytokine production. The relevance of this finding is evident in both viral infection and autoimmunity. Ablation of Nlrc3 led to enhanced antiviral cytokine production and improved control of LCMV. In parallel, Nlrc3 À/À mice exhibited hyper-inflammatory T cell responses in the EAE model and displayed more severe paralysis than wild-type mice. Gene profiling also indicated that NLRC3 affects Th1 and Th17 effector cells, an observation found in both the EAE model in mice and human MOG-specific CD4 + T cells from MS patients. Mechanistically, NLRC3 reduced NF-kB activation by attenuating K63-linked ubiquitination of TRAF6 in T cells after TCR stimulation. This is consistent with a previous study showing that NLRC3 impedes K63 ubiquitination of TRAF6 to attenuate NF-kB activation in peritoneal macrophages . The effect of NLRC3 on NF-kB activation was also observed in vivo after adoptive transfer of CD4 + T cells. NF-kB activation regulates glycolysis after T cell stimulation, whereas the glycolytic pathway promotes optimal proliferation and inflammatory cytokine production in Th1 cells (Peng et al., 2016) . However, the activation of CD4 + T cells, but not CD8 + T cells, is also accompanied by an increase in oxidative metabolism (Cao et al., 2014) . The dual reduction of glycolysis and oxidative metabolism by NLRC3 could explain the suppressive effect of NLRC3 on CD4 + T cells but not on CD8 + cells, although this remains to be explored. The negative regulatory function of NLRC3 is consistent with its reduced expression in activated CD4 + T cells, suggesting that activation of these cells requires the lowering of Nlrc3 expression to permit proliferation and inflammatory cytokine induction. In total, these findings define NLRC3 as a checkpoint protein of CD4 + T lymphocyte activation.
Although the roles of PRRs among innate immune cells are well described, their functions in T cells are less studied. Among TLRs, TLR2 is the most widely expressed in T cells (Imanishi et al., 2007) , and its role in T cell proliferation and IFN-g production is documented (Reynolds and Dong, 2013) . TLR2 promotes Th17 cell proliferation and cytokine production, and the loss of TLR2 in CD4 + T cells dramatically ameliorates EAE (Reynolds et al., 2010) . TLR4 signaling also directly regulates CD4 + T cells function (Gonzá lez-Navajas et al., 2010). Finally, the TLR adaptor MyD88 augments PI-3 kinase signaling in T cells (Gelman et al., 2006) . The expression of most NLRs in T cells is low to nil. However, Nlrp12 À/À mice develop an atypical EAE disease via enhanced IL-4 production in T cells (Lukens et al., 2015) , and another EAE study reached a different conclusion to suggest that NLRP12 mitigates inflammatory myeloid cells (Gharagozloo et al., 2015) . Similar to NLRP12, NLRP3 can bind and regulate the Il4 promoter (Bruchard et al., 2015) . No study has shown a role for NLR in IFN-g expression in T cells. TCR signaling results in the activation of membrane proximal events followed by downstream signals NF-kB, NFAT and AP-1, which lead to IFN-g production by T cells. NLRC3 did not cause detectable changes in proximal TCR signals but rather reduced downstream immune signaling, which is consistent with its role in the cytosol. Our findings are consistent with the notion that NLRC3 acts in a T-cell-intrinsic fashion to limit CD4 T cells sustained cytokine responses at times when WT T cell responses had subsided, suggesting that NLRC3 might be involved in resolving immune responses during protracted infection. It is also notable that the inhibitory role of NLRC3 on T cells is moderate, suggesting that it acts as a rheostat rather than an on-off switch. Hence, NLRC3 might be attractive as a target of checkpoint blockade because its inhibition could improve T cell responses without precipitating overt auto-immunity. In summary, we have identified NLRC3 as a negative CD4 + T cell regulator affecting both Th1 and Th17 cells in a T-cell-intrinsic fashion to limit cellular activation, proliferation, and downstream IFN-g and TNF expression through interference with NF-kB signaling. Nlrc3 À/À mice showed exacerbated T-cell-mediated autoimmunity and prolonged CD4 + T cell responses to virus infection, suggesting that NLRC3 acts as an intrinsic attenuator of T cell activity. NLRC3-targeted therapies could be attractive as treatment strategies for alleviating T-cell-mediated inflammatory disease or for resolving chronic viral infection. Consistent with our findings, a recent paper has reported that NLRC3 attenuates Th1 and Th17 responses during M. tuberculosis infection, indicating that NLRC3 also lowers T cell response against bacteria (Hu et al., 2018) . Together, these results indicate that NLRC3 serves as a general mitigator of CD4 + T cell activation in response to viruses, bacteria, and auto-antigens.
STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Nlrc3
À/À mice have been previously described , Zhang et al., 2014 . C57BL/6J (WT), 2D2 TCR transgenic mice and Rag1 À/À mice were purchased from The Jackson Laboratory. SMARTA TCR transgenic mice were provided by Dr. Jason K.
Whitmire at the University of North Carolina. Nlrc3 À/À mice were crossed with SMARTA TCR transgenic mice to generate SMARTA Tg + Nlrc3 À/À mice and with 2D2 TCR transgenic mice to generate 2D2 Tg + Nlrc3 -/-mice. Mice were bred and maintained in specific pathogen-free conditions in the animal facilities at UNC-Chapel Hill. All mice used for experiments were between 8 to 12 weeks of age and female mice were used in EAE experiments. All mouse studies were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and Institutional Animal Care and Use Committee guidelines of the University of North Carolina Chapel Hill.
Virus
Mice received 2 3 10 5 plaque-forming units (PFU) of the LCMV Armstrong strain by intraperitoneal injection or 2 3 10 6 PFU of the LCMV Clone13 strain by intravenous tail-vein injection. Viral stocks of LCMV were generated from infected BHK-21 cells. Viral titer in serum, liver, lung, and kidney were quantified by plaque assay on Vero cell monolayers.
EAE
EAE was induced in age-matched WT and Nlrc3
À/À female mice by subcutaneous injection of 250 mg MOG 35-55 peptide per mouse emulsified in complete Freund's adjuvant (CFA). The dosage of total heat-killed Mycobacterium tuberculosis was 200 mg per mouse. On days 0 and 2, mice received intraperitoneal injection of 200 ng pertussis toxin. Symptoms of EAE were monitored daily using a standard clinical score ranging from 0 to 5 as follows: 0, asymptomatic; 1, tail paralyzed; 2, hind limb paresis; 3, both hind limbs paralyzed; 4, forelimbs paralyzed; and 5, moribund, as previously described (Stromnes and Goverman, 2006) .
METHOD DETAILS
In vitro CD4 + T cell activation assay Spleen cells were isolated from WT and Nlrc3 À/À mice. CD4 + T cells were negatively selected using mouse CD4 + T Cell Isolation Kit or EasySep TM . Mouse Naive CD4 + T cell Isolation Kit. Cells were cultured in 96 round-bottom plates with plate-bound anti-CD3 (1 to 5 mg/mL) and soluble anti-CD28 (2 mg/mL) antibodies or soluble PMA (50 ng/mL) and Ionomycin (1 mg/mL) in complete RPMI1640 media with 10% fetal bovine serum, 1% penicillin, 100 mg/mL streptomycin, 4 mM L-glutamine, 55 mM 2-Mercaptoethanol, 1 mM sodium pyruvate, and nonessential amino acids.
CD4
+ T cell adoptive transfer Spleens were removed from naive WT and Nlrc3 À/À mice, and CD4 + T cells were positively selected from the splenocytes population using L3T4 MicroBeads. CD4 + T cells (2.5 3 10 6 per mouse) were injected via tail vein injection into Rag1 À/À female mice. One day later, the recipient mice were subjected to EAE induction. . A heatmap of mouse RNA-seq data was generated as described above for human data.
Ubiquitination assay
For in vitro ubiquitination assay, 2 3 10 6 primary mouse CD4 + T cells were stimulated by anti-CD3 (5 mg/mL) and anti-CD28 (1 mg/mL) and then lysed 0, 5, and 10 min later in 100 ml 2% SDS isotonic buffer (50 mM Tris, pH 7.8, 150 mM NaCl, 1% (vol/vol) Nonidet-P40, 2% SDS and 10% (vol/vol) glycerol). Lysates were boiled for 15 min for removal of any noncovalent interactions, and then were centrifuged for 10 min at 16,000 g, and then supernatants were transferred to a new tube. Lysates were diluted 10-fold with 1% Triton X-100 buffer (50 mM Tris, pH 7.8, 150 mM NaCl, 1% (vol/vol) Nonidet-P40 and 10% (vol/vol) glycerol) and substrate molecules were immunoprecipitated with anti-TRAF6 and protein G Sepharose beads. TRAF6 and K63 ubiquitination of TRAF6 was detected by western blot with anti-TRAF6 and anti-K63 Ub respectively.
Western Blot
Spinal cords were homogenized in RIPA lysis buffer supplemented with complete proteinase inhibitor cocktail and PhoSTOP phosphatase inhibitors. Primary cells were lysed in RIPA buffer. Protein lysates were cleared of insoluble material through centrifugation, and the resulting protein lysates were subjected to SDS-PAGE. Proteins were wet transferred to 0.2 mm nitrocellulose membranes (BioRad Laboratories), which were blocked using 5% non-fat milk in 1% TBS-T buffer for 1 hr at room temperature. The membranes were incubated overnight using the following primary antibodies: anti-actin HRP, anti-Histone H3, anti-p65, anti-pp65, anti-STAT1, anti-pSTAT1, anti-ZAP70, anti-pZAP70, anti-PLC-g1, anti-pPLC-g1, anti-NFAT1, anti-mTOR, anti-pmTOR, anti-AKT, anti-pAkt, antiAkt, anti-4EBP1, anti-p4EBP1, anti-S6K, anti-pS6K, anti-c-Myc, anti-pc-Myc, anti-JNK, anti-pJNK, anti-ERK1/2 or anti-pERK1/2. All primary antibodies were used at a 1:1,000 dilution in 5% non-fat milk. Membranes were washed in TBS-T and incubated with the following appropriate secondary antibodies: goat anti-rabbit-HRP or goat anti-mouse HRP. All secondary antibodies were used at a 1:40,000 dilution in 5% non-fat milk. Protein bands were visualized following exposure of the membranes to ECL substrate solution (ThermoFisher) and quantified by densitometryc analysis using ImageJ software.
Metabolism Assays CD4 + T cells were isolated from WT and Nlrc3 À/À mice and stimulated with anti-CD3 and anti-CD28 antibodies with or without the NF-kB inhibitor (BAY 11-7082 or QNZ) for 24 hr. The cells were then plated in glucose-free media with 100 mM sodium pyruvate and 2mM glutamine for ECAR measurements and with 100 mM sodium pyruvate and 2.5 M glucose for OCR measurements for 1 hr in absence of CO 2 at 37 C prior to the start of the metabolism assay. ECAR and OCR rates were assessed at basal conditions and after the addition of glucose (10 mM), oligomycin (1mM), and 2-Deoxyglucose (20 mM) for ECAR, and after the addition of oligomycin (1mM), FCCP (1 mM), and rotenone (1mM) for OCR. Compounds were added at the indicated time points and the assay was performed using a Seahorse Extracellular XF24 analyzer. Three measurements were recorded for basal metabolic rates and following each injection QUANTIFICATION AND STATISTICAL ANALYSIS P values less than 0.05 were considered statistically significant for all datasets. Statistical significance between two groups was assessed by unpaired t tests. Statistical analyses and graphing of data were performed using GraphPad PrismÒ Software.
